PatientsVille.com Logo

VISION BLURRED and Azithromycin

PatientsVille

VISION BLURRED Symptoms and Causes

What is high blood pressure in pregnancy?

Blood pressure is the force of your blood pushing against the walls of your arteries as your heart pumps blood. High blood pressure, or hypertension, is when this force against your artery walls is too high. There are different types of high blood pressure in pregnancy:

  • Gestational hypertension is high blood pressure that you develop while you are pregnant. It starts after you are 20 weeks pregnant. You usually don't have any other symptoms. In many cases, it does not harm you or your baby, and it goes away within 12 weeks after childbirth. But it does raise your risk of high blood pressure in the future. It sometimes can be severe, which may lead to low birth weight or preterm birth. Some women with gestational hypertension do go on to develop preeclampsia.
  • Chronic hypertension is high blood pressure that started before the 20th week of pregnancy or before you became pregnant. Some women may have had it long before becoming pregnant, but didn't know it until they got their blood pressure checked at their prenatal visit. Sometimes chronic hypertension can also lead to preeclampsia.
  • Preeclampsia is a sudden increase in blood pressure after the 20th week of pregnancy. It usually happens in the last trimester. In rare cases, symptoms may not start until after delivery. This is called postpartum preeclampsia. Preeclampsia also includes signs of damage to some of your organs, such as your liver or kidney. The signs may include protein in the urine and very high blood pressure. Preeclampsia can be serious or even life-threatening for both you and your baby.
What causes preeclampsia?

The cause of preeclampsia is not known.

Who is at risk for preeclampsia?

You are at higher risk of preeclampsia if you

  • Had chronic high blood pressure or chronic kidney disease before pregnancy
  • Had high blood pressure or preeclampsia in a previous pregnancy
  • Have obesity
  • Are over age 40
  • Are pregnant with more than one baby
  • Are African American
  • Have a family history of preeclampsia
  • Have certain health conditions, such as diabetes, lupus, or thrombophilia (a disorder which raises your risk of blood clots)
  • Used in vitro fertilization, egg donation, or donor insemination
What problems can preeclampsia cause?

Preeclampsia can cause

  • Placental abruption, where the placenta separates from the uterus
  • Poor fetal growth, caused by a lack of nutrients and oxygen
  • Preterm birth
  • A low birth weight baby
  • Stillbirth
  • Damage to your kidneys, liver, brain, and other organ and blood systems
  • A higher risk of heart disease for you
  • Eclampsia, which happens when preeclampsia is severe enough to affect brain function, causing seizures or coma
  • HELLP syndrome, which happens when a woman with preeclampsia or eclampsia has damage to the liver and blood cells. It is rare, but very serious.
What are the symptoms of preeclampsia?

Possible symptoms of preeclampsia include

  • High blood pressure
  • Too much protein in your urine (called proteinuria)
  • Swelling in your face and hands. Your feet may also swell, but many women have swollen feet during pregnancy. So swollen feet by themselves may not be a sign of a problem.
  • Headache that does not go away
  • Vision problems, including blurred vision or seeing spots
  • Pain in your upper right abdomen
  • Trouble breathing
  • Eclampsia can also cause seizures, nausea and/or vomiting, and low urine output. If you go on to develop HELLP syndrome, you may also have bleeding or bruising easily, extreme fatigue, and liver failure.

    How is preeclampsia diagnosed?

    Your health care provider will check your blood pressure and urine at each prenatal visit. If your blood pressure reading is high (140/90 or higher), especially after the 20th week of pregnancy, your provider will likely want to run some tests. They may include blood tests other lab tests to look for extra protein in the urine as well as other symptoms.

    How is preeclampsia treated?

    Delivering the baby can often cure preeclampsia. When making a decision about treatment, your provider take into account several factors. They include how severe it is, how many weeks pregnant you are, and what the potential risks to you and your baby are:

    • If you are more than 37 weeks pregnant, your provider will likely want to deliver the baby.
    • If you are less than 37 weeks pregnant, your health care provider will closely monitor you and your baby. This includes blood and urine tests for you. Monitoring for the baby often involves ultrasound, heart rate monitoring, and checking on the baby's growth. You may need to take medicines, to control your blood pressure and to prevent seizures. Some women also get steroid injections, to help the baby's lungs mature faster. If the preeclampsia is severe, you provider may want you to deliver the baby early.

    The symptoms usually go away within 6 weeks of delivery. In rare cases, symptoms may not go away, or they may not start until after delivery (postpartum preeclampsia). This can be very serious, and it needs to be treated right away.

Check out the latest treatments for VISION BLURRED

VISION BLURRED treatment research studies

Azithromycin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Azithromycin Side Effects

Diarrhoea (164)
Nausea (131)
Vomiting (123)
Dyspnoea (120)
Dizziness (97)
Rash (91)
Pain (75)
Headache (68)
Abdominal Pain Upper (68)
Pruritus (66)
Abdominal Pain (64)
Asthenia (63)
Pyrexia (59)
Urticaria (56)
Malaise (55)
Anxiety (52)
Tinnitus (42)
Hypotension (42)
Hypersensitivity (42)
Cough (40)
Electrocardiogram Qt Prolonged (40)
Pulmonary Embolism (40)
Loss Of Consciousness (39)
Renal Failure Acute (39)
Condition Aggravated (39)
Cardiac Arrest (38)
Insomnia (36)
Pneumonia (35)
Erythema (34)
Weight Decreased (34)
Palpitations (33)
Injury (33)
Chills (31)
Pain In Extremity (31)
Fatigue (31)
Oedema Peripheral (31)
Dehydration (30)
Hyperhidrosis (30)
Tachycardia (30)
Stevens-johnson Syndrome (30)
Rhabdomyolysis (28)
Deep Vein Thrombosis (28)
Deafness (28)
Cholecystitis Chronic (26)
Product Quality Issue (26)
Syncope (26)
Heart Rate Irregular (25)
Feeling Abnormal (25)
Chest Pain (25)
Heart Rate Increased (24)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

I am sorry you are in pain. But did you not just say you have Pneumonia!? I think that life threatening infection is worse than the diarrhea dont you?

A doctor subscribed this medication to me for a flu. On the 3rd day I had soft tissue blisters in my nose and my nose was swollen. Also my glands under my neck/jaw were sore. The 4th day my checks and jaws also swole up. *DONT_KNOW*

A week after finish the course of 5 day treatment. Itchy red rash developing all over my legs, very itchy. Wonder if I need to go back to my doctor.

Dear, Kindly ref my earlier post on 21/9/10. After 35 days of medication against side effects of azithromycin from different doctors, finally at the end of september 20

Definitely seems to cause a very down mood! Why don't they know this?

Diarrhea after eating. Bad headaches.

Elizabeth, I lost my sense of smell and my taste too. That was 3rd of May 2011. It is 8th of August and I still havent got it back yet. Have you got yours back yet?

Extreme sensitivity of joints experienced - especially hip, knee, ankle - which has effectively rendered walking painful and difficult. Suspicion of impact on tendons, sharp pain around shoulder blades on certain habitual movements, pressur

Got into a deep depression in 96 after taking zithromax and again in 2007 after the same medication. It started with major panick attacks and anxiety and just got worse. The first time I did not think the medication caused it but when it happened the

Hello will Azithromycin make you not sleep ever since i have been taking this i have not slept but 6 hours in three days?

fROM THE DAY i GOT THE INJECTION aCLASTA, i AM FEELING GIDDY AND HAVE LOST MY VISION. w WHAT IS YOUR RESPONSIBILITY ABOUT THIS fROM THE DAY i GOT aCLASTA INJECTION, i AM FEELING

Blurred vision, giddiness,Tiredness,Swelling on feet and hands

M 23 of age.. And via consultant i am taking seroxat(20mg)... about two mouths ago..but still sharp headache occured daily n morning...plus my vision gets blurred n morning..don't nw why..its really annoying... Lik eithr its a medicn side effects o

can advagraf makke you look like you are pregnant? Can this drug affect your eye site--blurry vision

Started taking Bystolic 5mg on Thursday for tachycardia. Sunday, had blurred vision. (Was driving and it was so bad that the interstate signs were blurred!) Stopped medicine and called doctor on Monday. Tuesday, called back because nobody saw f

<b>Describe Your Seroxat Experience Here:</b>Stomach and wierd vision and feeling tired

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

<span style='color: #808080;'><b>My son complained of not being able to see to well so I took him to lenscrafters to check his vision since he wore glasses before and had lost them. No big deal I thought, anyway they took some t

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

VISION BLURRED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting Mortality Reduction After Oral Azithromycin: Mortality Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: All-cause Mortality Rate in children aged 1-60 months;   Cause-specific Mortality Rate in children aged 1-60 months, as assessed from verbal autopsy;   Cost-effectiveness of mass Azithromycin administration, per averted childhood death;   All-cause and cause-specific health clinic visits in 1-60 month-old children
2 Recruiting Trial of Intravenous Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants
Condition: Ureaplasma Infections
Interventions: Drug: Azithromycin;   Drug: Placebo (for Azithromycin)
Outcome Measures: Survival with microbiological eradication of Ureaplasma;   Physiologic defined bronchopulmonary dysplasia (BPD) at 36 weeks post menstrual age;   Death or Neurodevelopmental impairment;   Pulmonary impairment;   Death;   Duration of positive pressure support;   Duration of oxygen supplementation;   Air leaks;   Received postnatal steroids;   Received Non-Study antibiotics;   Pharmacokinetics (PK)/Pharmacodynamics (PD) modelling of time course of Azithromycin plasma concentrations
3 Not yet recruiting Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis
Conditions: Malaria, Falciparum;   Chloroquine;   Azithromycin;   Immunization
Interventions: Drug: Azithromycin capsules;   Drug: Placebo;   Biological: Immunization with falciparum;   Drug: Atovaquone/Proguanil;   Biological: Challenge with falciparum
Outcome Measures: Volunteers falciparum positive by thick smear;   Duration of pre-patent period by thick smear;   Kinetics of parasitemia by PCR;   Adverse events;   Immune responses
4 Not yet recruiting Mortality Reduction After Oral Azithromycin: Morbidity Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Presence of malaria parasites on thick blood smear in children 1-60 months;   Fraction of isolates of pneumococcus exhibiting macrolide resistance by nasopharyngeal swabs in children 1-60 months;   Fraction of isolates of Staphylococcus aureus exhibiting macrolide resistance by nasal swabs in children 1-60 months;   Fraction of isolates of Streptococcus pyogenes exhibiting macrolide resistance by oropharyngeal swabs in children 1-60 months;   Evidence of E. coli macrolide resistance in stool specimens in children 1-60 months;   Fraction of conjunctival swabs yielding ocular chlamydia in children 1-60 months;   Height over time in children aged 1-60 months;   Presence of malaria gametocytes, and density of malaria parasites and gametocytes, in children 1-60 months;   Rates of malaria parasitemia among children 1-59.9 months.;   Hemoglobin concentration and presence of anemia (hemoglobin <11 g/dL) in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance in individuals 7-12 years;   Nasopharyngeal pneumococcal macrolide resistance in children aged 1-60 months seen in local health clinics for a respiratory complaint;   Rates of acute respiratory illness among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Presence of the trachoma grades "follicular trachoma" (TF) and "intense inflammatory trachoma" (TI), as defined by the WHO simplified grading system, in children 1-60 months;   Trachoma infection and antibody status in children (1-60 months);   Rates of diarrhea among children 1-59.9 months.;   Carriage rates and proportions E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months;   Carriage rates and proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months;   Nasopharyngeal methicillin-resistant Staphylococcus aureus in children 1-60 months;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Nasopharyngeal pneumococcal resistance to penicillin and clindamycin in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance determinants (ermB and mefA), serotype, and multilocus sequence type in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance to penicillin and clindamycin in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance determinants (mefA, ermB, ermTR) in children 1-60 months;   Microbial diversity in the conjunctival, nasopharyngeal, nasal, oropharyngeal, and intestinal microbiomes of children aged 1-60 months;   Serology for exposure to exotic pathogens cross sectional sample of children aged 1-60 months;   Knee-heel length and head circumference over time in children aged 1-60 months;   Commensal and diarrheagenic E. coli carriage in stool of children aged 1-60 months
5 Recruiting Trial for the Treatment of Acute Asthma in Wheezy Pre-school Aged Children
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Suspension Placebo
Outcome Measures: To determine if treatment of pre-school children with a history of wheeze who present to an Emergency department (ED) with an acute wheezing episode with Azithromycin for 5 days will resolve their symptoms more quickly;   Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will cause these children to use less rescue beta2 agonists than those treated with placebo;   Treatment of pre-school children with acute wheezing symptoms with 5 days of Azithromycin will allow these children to remain free of subsequent wheezy episodes longer than those treated with placebo.
6 Not yet recruiting Belgian Trial With Azithromycin During Acute COPD Exacerbations
Condition: Chronic Obstructive Pulmonary Disease
Intervention: Drug: Azithromycin
Outcome Measures: Time to treatment failure;   Number of treatment failures;   Time to new exacerbation;   Number of new exacerbations;   Rate of exacerbations;   Days of hospitalisation;   Days of intensive care;   Symptom and quality of life scores;   Pre- and post-bronchodilator FEV1;   Total dose of systemic steroids;   Total days of antibiotic use;   Number of home physician contacts;   Average cost of hospitalization
7 Not yet recruiting Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection
Conditions: Ocular Inflammation;   Infection Associated Blepharitis;   Keratitis;   Conjunctivitis, Bacterial
Interventions: Drug: Azithromycin 1.5%/Loteprednol 0,5% + placebo;   Drug: Azithromycin 1.5% + Loteprednol 0,5% (separately)
Outcome Measures: Clinical cure;   irradication of pathogens
8 Recruiting Azithromycin for Children Hospitalized With Asthma
Condition: Asthma
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Length of Stay;   Readmission rate;   School missed;   Work missed;   Emergency room visits;   Physician office visits;   Recurrence of asthma symptoms;   Steriod courses
9 Recruiting Trial Of Azithromycin In Campylobacter Concisus Patients With Diarrhea
Conditions: Diarrhea;   Fever;   Vomiting;   Abdominal Pain
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Duration of diarrhea in days;   number of stools/day
10 Recruiting A Surveillance and Azithromycin Treatment for Newcomers and Travelers Evaluation: The ASANTE Trial
Condition: Trachoma
Intervention: Other: Surveillance and treatment with Azithromycin of newcomer and traveler families
Outcome Measures: The proportion of communities with C. trachomatis infection prevalence of 1% or below;   The proportion of communities with clinical trachoma prevalence of 5% or below;   The trajectory of change in prevalence of infection with C. trachomatis and clinical trachoma;   The community prevalence of new infections of C. trachomatis and clinical trachoma identified;   The presence of active trachoma in children;   The presence of trachomatous scarring in women
11 Recruiting Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation
Condition: Disorder Related to Lung Transplantation
Interventions: Drug: Azithromycin;   Drug: Ora-Plus
Outcome Measures: Mean forced expiratory volume at one second (FEV1, %pred);   Length of intubation;   Length of Intensive Care Unit (ICU) stay;   Length of hospital stay;   Partial Pressure of Oxygen in Arterial Blood over fraction of inspired oxygen fraction - ratio (PaO2/FiO2);   Primary graft dysfunction (PGD) prevalence and score;   6-minute walking distance;   Acute rejection (grade A; grade B) prevalence/severity;   Broncho-alveolar lavage neutrophilia and cytokine/protein profile;   Airway colonization;   Plasma C-reactive protein levels;   Mortality;   Ventilator-free days
12 Recruiting Drug Interaction Study of Azithromycin and Theophylline
Conditions: Chronic Obstructive Pulmonary Disease;   Asthma
Interventions: Drug: Theophylline with Azithromycin;   Drug: Theophylline alone
Outcome Measure: steady-state plasma concentration of theophylline
13 Unknown  Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Condition: Cutaneous Leishmaniasis
Interventions: Drug: N-metil glucamine;   Drug: Azithromycin
Outcome Measures: Proportion of clinically cured patients;   Proportion of patients with failure;   Occurrence of mucosal lesions after treatment;   Proportion of patients presenting new lesions;   Proportion of adverse events on each treatment group
14 Recruiting PASS Study To Evaluate The Potential Of Zithromax To Cause Ocular Problems In Pediatric Patients
Conditions: Pharyngitis;   Tonsillitis
Intervention: Drug: Azithromycin
Outcome Measure: Best corrected visual acuity (distance), color vision, Amsler grid testing, anterior segment biomicroscopy, and fundus examination
15 Recruiting Azithromycin Against pLacebo in Exacerbations of Asthma
Condition: Asthma
Interventions: Drug: Zithromax;   Drug: Placebo
Outcome Measures: Diary card summary symptom score;   Quality of life;   Time to 50% reduction in symptom score;   Pulmonary Function tests
16 Recruiting Azithromycin Based Therapy for Induction of Remission in Active Pediatric Crohn's Disease
Condition: Crohn's Disease
Interventions: Drug: Azithromycin + Metronidazole;   Drug: Metronidazole
Outcome Measures: Response rate at 8 weeks defined as a drop in PCDAI (Pediatric Crohn's Disease Activity Index ) of at least 12.5 points (or remission without steroids, intention to treat principle);   Normalization of CRP ( CRP ≤0.5 mg/dL).;   Fecal calprotectin at 8 weeks .
17 Recruiting Efficacy of Azithromycin Prophylaxis in Preventing Recurrent Acute Sinusitis in Children
Condition: Sinusitis
Interventions: Drug: placebo;   Drug: Azithromycin
Outcome Measure: frequence of acute sinusitis during 12 mouths of study period
18 Unknown  The Efficacy of Prednisone and Azithromycin in the Treatment of Patients With Cat Scratch Disease
Conditions: Cat-scratch Disease;   Bartonella Infections
Interventions: Drug: prednison and Azithromycin;   Drug: prednison, Azithromycin;   Drug: prednison, Azenil
Outcome Measure: Severity score of lymphadenitis using a lymphadenitis Score (LS).
19 Recruiting Prevention of Bacterial Infections in Newborn
Condition: Neonatal Infection
Intervention: Drug: Azithromycin and Placebo
Outcome Measures: the prevalence of nasopharyngeal carriage of the newborn of any of the following bacteria: 1) Group B Streptococci (GBS) , 2) S.pneumoniae and 3) S.aureus;   Vaginal bacterial Group B Streptococci(GBS), S.pneumoniae and S.aureus) carriage at day six post-delivery. Vaginal bacterial (GBS, S.pneumoniae and S.aureus) carriage at day 8-10 post-delivery
20 Unknown  the Comparison Efficacy of Azithromycin With Doxycycline in the Treatment of Acne Vulgaris
Condition: Acne
Interventions: Drug: Doxycycline;   Drug: Azithromycin
Outcome Measures: change in acne lesions;   global response rates, patient's own assessment, side effects and compliance